Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself.
Cardoso
F
F
Department of Medicine, Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium. fatima.cardoso@bordet.be
Dal Lago
L
L
Braga
S
S
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism
D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone